On Thursday, Deutsche Bank AG (USA) (NYSE:DB)’s shares inclined 0.26% to $27.41.
A former Deutsche Bank AG executive fired when female colleagues accused him of sexual harassment won a discrimination lawsuit after London judges ruled the women had lied, exaggerated and used lewd language themselves, according to Bloomberg.
Konrad Joy, who was chief operating officer in the global risk department, reached a settlement with the bank after the London Employment Tribunal ruled in his favor. The decision, issued in December and only released this week, criticized the bank’s handling of the complaints.
Many of the accusations were “simply accepted at face value, not investigated further,” the judges said, and the bank’s investigation had been “very poor.”
Deutsche Bank initially appealed the decision, but later decided to settle the case on confidential terms. Joy, 44, had been seeking as much as 20 million pounds ($30 million) in compensation. Bloomberg Reports
Deutsche Bank AG is a global investment bank, which offers a range of products and services in investment, corporate and retail banking, as well as in asset and wealth management.
Brocade Communications Systems, Inc. (NASDAQ:BRCD)’s shares gained 1.72% to $10.62.
Brocade Communications Systems, will host and conduct a live webcast of its annual Investor Day on Wednesday, Sept. 30, 2015, in order to provide planned direction on the company’s business and initiatives, and to provide a financial update.
Taking place from 9 a.m. to 12 p.m. PT, the event will feature presentations from Brocade’s executive leadership:
- Lloyd Carney, Chief Executive Officer
- Jack Rondoni, Vice President, Storage Networking
- Jason Nolet, Senior Vice President, Switching, Routing, and Analytics Products Group
- Kelly Herrell, Senior Vice President and General Manager, Software Networking Group
- Dan Fairfax, Chief Financial Officer
Brocade Communications Systems, Inc. (Brocade) is a supplier of networking equipment, including end-to-end Internet Protocol-based Ethernet networking solutions and storage area networking solutions for businesses and organizations of all types and sizes, including global enterprises, and service providers, such as telecommunication firms, cable operators and mobile carriers.
At the end of Thursday’s trade, Axalta Coating Systems Ltd (NYSE:AXTA)‘s shares dipped -2.18% to $26.42.
Research analysts have given Axalta Coating Systems Ltd. (NYSE:AXTA) a consensus one year price target of $34.40. This is the average number based on the brokerages polled by Thomson Reuters’ First Call. These same sell-side analysts are expecting that the company will report $0.28 earnings per share next quarter and earnings of $1.15 per share for the current year.
Axalta Coating Systems Ltd. is a manufacturer, marketer and distributor of coatings systems primarily serving the transportation industry. The Company operates in two business segments: Performance Coatings and Transportation Coatings. Through its Performance Coatings segment, the Company provides liquid and powder coatings solutions to a fragmented and local customer base.
Orexigen Therapeutics, Inc. (NASDAQ:OREX), ended its Thursday’s trading session with -7.44% loss, and closed at $2.24.
Orexigen Therapeutics declared receipt of the first of three potential $15 million anniversary milestone payments from Takeda Pharmaceuticals, Orexigen’s United States partner for Contrave® (naltrexone HCl and bupropion HCl extended release). Two additional potential $15 million anniversary milestone payments are predictable from Takeda in the fourth quarter of each of 2016 and 2017.
Orexigen also declared receipt of the $7 million upfront payment from Kwang Dong Pharmaceutical Company Ltd., based in Seoul, Korea. In August 2015, Orexigen and Kwang Dong executed a Korean distributorship agreement for Contrave. Kwang Dong anticipates to start marketing Contrave in the second half of 2016, if regulatory approval is obtained.
Orexigen anticipates to end 2015 with about $190 – 200 million in cash and cash equivalents.
Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company’s product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
